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Abstract 
HZ/Su, branded as ‘Shingrix’, is one of the newest vaccines to be submitted for multi-
national regulatory approval. It is targeted to prevent shingles, predominantly affecting the 
elderly, but a global concern with ageing populations and significant associated morbidity 
and mortality. A vaccine for shingles has been available for over a decade, however it is 
contraindicated in specific subgroups of people, and there are added concerns regarding 
long-term immunogenicity. HZ/Su is the first subunit vaccine developed to protect against 
shingles. This paper provides a critical appraisal of current evidence regarding HZ/Su.  
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Introduction 
Endemic worldwide, varicella zoster virus (VZV) is a highly neurotropic and T-cell tropic 
alphaherpes virus. Primary infection leads to the common clinical condition, varicella or 
‘chickenpox’. Subsequently, VZV remains dormant in sensory dorsal root ganglia, with the 
potential for reactivation in one or more sensory neurones leading to herpes zoster (HZ) or 
‘shingles’, and complications such as postherpetic neuralgia (PHN) (1). The incidence of HZ 
in the United States and Europe increases with advanced age is estimated at 3 to 10 cases 
per 1000 person-years (2). For unclear reasons this incidence has steadily increased with 
time (3). A vaccine for varicella has been available since 2002, and production and licensing 
of a live-attenuated vaccine for HZ occurred in 2006 (4). Notably, there are contra-
indications to live-attenuated vaccines, such as VZV naive or immunosuppressed patients in 
whom vaccination may cause disease. We critical appraise published data on a novel 
subunit vaccine for VZV, HZ/Su or GSK1437173A (GSK). 
- Virology  
VZV is an enveloped, spherical to pleomorphic double-stranded DNA virus with a 
monopartite genome approximately 125 kilobases, illustrated in Figure 1 and 2. The genome 
encodes at least 71 open reading frames (ORFs) and related promoter sequence. 
Approximately two thirds of the ORFs are necessary for replication, and this includes 40 
genes common among all herpes viruses (5). Glycoprotein E (gE) is a large unique N 
terminus (amino acids 1–187) essential for replication and T-cell entry. This is the most 
abundant and immunogenic glycoprotein, and the target utilised in the HZ/Su vaccine. 
Figure 3 summarises the natural history of the virus, and the basic cell mechanism of viral 
replication.  
- Immunology 
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During primary infection, the initial immune response to VZV involves the innate immune 
system, with the release of antiviral cytokines and the activation of NK cells (1). This is 
suggested to control viral replication in the mucosa, as well as triggering adaptive immunity. 
Memory immunity to VZV involves persistence of VZV IgG and VZV-specific CD4 and CD8 
cells, however it is cell-mediated immunity that correlates best with the severity of primary 
infection (6). The cell-mediated response is crucial for preventing reactivation of latent VZV 
residing in ganglionic cells. This immunity naturally wanes over time, and this is thought to 
be the reason HZ chiefly afflicts the elderly.  
Delineating this further, a strong VZV-specific CD4 response at the onset of HZ is associated 
with improved clinical outcomes. Within a cohort of patients who developed HZ in the 
Shingles Prevention Study (SPS) increased expression of IFN-γ in peripheral blood 
mononuclear cells (PMBCs) after stimulation with VZV antigen was associated with reduced 
morbidity and a lower incidence of PHN (8). The frequency of VZV-specific memory T cells 
present predicted development of HZ and severity. Subjects who did not develop HZ during 
follow up tended to have higher baseline frequencies of VZV-specific T cells when compared 
to subjects who subsequently developed HZ. Both administration of the attenuated zoster 
vaccine or an episode of HZ resulted in an increase in VZV-specific T cells in subjects (9). 
Interestingly levels of anti-VZV antibodies did not correlate with protection against HZ, 
matching previous observations (10). It is essential therefore that an effective vaccine to 
prevent HZ elicits a sustained cellular immune response against VZV.    
- Nature of the disease 
The reactivation of latent VZV residing in the dorsal root ganglion, see Figure 3, has been 
demonstrated to involve a decline in cell-mediated immunity (11). Risk factors include older 
age, cell-mediated immune dysfunction, diabetes, female gender, genetic susceptibility, 
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mechanical trauma, recent psychological stress and white race (12). The clinical 
presentation involves three phases: 1) Prodrome, 2) Infectious rash and 3) Resolution. The 
prodrome of acute neuralgia may precede the rash by 2-100 days (1). The rash typically 
involves a single dermatome, with an erythematous macular rash followed by vesicular 
lesions that ulcerate, scars and heals. Data suggests that complications occur in 12% (13). 
Persisting pain, or pain which appears more than 90 days after symptom onset is termed 
postherpetic neuralgia and increases with age. Aside from the severe pain that may be 
associated with HZ, there are potentially devastating complications: secondary bacterial 
infection and sepsis, meningoencephalitis, visual and hearing impairment. It is suggested 
that up to 4% of persons who develop shingles attend secondary care.  
- Treatment 
Antiviral treatment with intravenous or oral Aciclovir, Valaciclovir or Famciclovir 
administered within 72 hours of symptoms onset, reduce the severity and duration of HZ 
(14). There are no licensed antivirals to reduce or prevent the onset of PHN, and 
management depends on supportive care such as analgesia.   
- Epidemiology and Public Health aspects: 
The estimated lifetime risk of HZ is 25-30%, and the subsequent risk of developing PHN is 
approximately 20% (3). In contrast to varicella, there is no seasonal distribution, and cases 
occur more frequently with increasing age (15). Exogenous exposure to VZV boosts the 
immune system and prevents reactivation. Undeniably, current epidemiological data has 
been focused in Europe, U.S.A. and Australia and it is in these settings that experience has 
been gained with the existing live-attenuated HZ vaccine, Zostavax. 
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Key issues 
 Primary VZV infection causes varicella, and reactivation causes shingles/Herpes 
Zoster.  
 Cell-mediated immunity prevents VZV reactivation, and is primed by repeated 
exogenous exposure to VZV. However, this immunity wanes with increasing age, 
leading to HZ in the elderly.  
 HZ is common, with 3-5 cases/person-year worldwide. Complications include sepsis 
due to secondary bacterial impairment, severe and persistent pain, visual and 
hearing impairment.  
 Persistent pain at least 90 days after the rash has healed, postherpetic neuralgia 
(PHN), is the commonest complication. This occurs in up to 1 in 5 patients, resulting 
in considerable morbidity. The incidence and severity of PHN increases with age.      
 Antivirals may shorten symptom duration and severity. However, they must be 
administered within 72 hours of symptom onset, and there is insufficient evidence to 
demonstrate a benefit in preventing postherpetic neuralgia.  
 Immunisation to prevent HZ has existed for over a decade in the form of a live-
attenuated vaccine, Zostavax. It is the only licensed HZ vaccine, now licensed in 50 
countries. 
 The efficacy of Zostavax to reduce the burden of illness of HZ falls from 61.1% at year 
four to 37.3% at eleven years post vaccination.  
 Zostavax is contraindicated in immunosuppressed patients, in whom vaccination 
may lead to disease.  
 “HZ/Su” or GSK1437173A varicella zoster vaccine (ShringrixTM) is a novel subunit 
vaccine based on glycoprotein E with AS01 as an adjuvant.  
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Zostavax, the existing shingles (HZ) vaccine 
The live-attenuated Oka strain was developed in Japan in the 1970s as a vaccine for the 
prevention of varicella (16). This was derived from VZV isolated from a 3-year-old boy with 
varicella, and passaged in human embryonic fibroblasts, guinea pig fibroblasts, and then in 
human diploid fibroblasts. Two decades later the same vaccine at a significantly higher 
concentration was successfully trialled for the prevention of HZ (17). This was based on 
Hope-Simpson’s theory that an episode of HZ would boost VZV-specific cell-mediated 
immunity and prevent another episode of HZ (18).  
The live-attenuated HZ vaccine was first licensed on the 19th May 2006. It is produced by 
Zostavax Merck/ Sanofi Pasteur for adults over 50 years of age, and costs $100-200 for a 
single dose.   
A recent Cochrane review included 10 randomised controlled trials of Zostavax. 4 studies 
were deemed to have a low risk for bias but overall, the vaccine reduced the incidence and 
complications of HZ (19). Vaccine efficacy however decreased with time and protection 
against the burden of illness from HZ reduced from 61.1% at year four, to 50.1% at year 
seven and 37.3% at year eleven. Efficacy in prevention of PHN similarly decreased from 
66.5% at year four to 35.4% at year eleven (20,21). Notably, the external validity of the 
study was low due to the homogeneity of the population.   
52 countries have now licensed Zostavax, and there has been variable introduction in 
immunisation policies and uptake. In the UK, the vaccine was deemed cost-effective for 70 
year olds. The decision was based on the milder symptoms and lower risk of complications 
in people aged under 70 years, and the limited efficacy above 80 years. 
Issues with Zostavax include preclusion of the vaccine to categories of immunosuppressed 
patients, the limited efficacy demonstrated beyond 5 years or in those patients over 80 
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years. There are concerns that Zostavax uptake has been low, and suggestions that there is 
lower confidence in a live-attenuated vaccine. It is for these reasons that an alternative may 
be necessary.  
Design and development of product  
The “HZ/su” or GSK1437173A varicella zoster vaccine (ShringrixTM) is an investigational 
subunit vaccine manufactured by GSK containing 50 μg of recombinant VZV glycoprotein E 
(gE) formulated with AS01B adjuvant.  
Glycoprotein E is a 90-98 kDa protein encoded by ORF68 and is the most abundant 
membrane found on VZV-infected cell membranes and present in high concentrations 
within the skin during episodes of HZ (22). gE is thought to be essential in facilitating VZV 
neurotropism and virulence represents a major target in the development of host immunity 
(5). Early studies demonstrated that primary infection results in development of anti-gE 
antibodies (23) and CD4 responses specific to gE (24) in human subjects. Monoclonal 
antibodies raised against gE neutralised infectious virions in vitro with the presence of 
complement (25). A recombinant, truncated gE molecule lacking the transmembrane anchor 
and carboxyterminal domains was immunogenic in mice and capable of stimulating 
production of neutralising antibodies (26). A subsequent gE fusion protein was also capable 
of stimulating specific humoral and T-cell responses in guinea pigs (27) supporting it as a 
potential candidate for subunit vaccine development.  
AS01 Adjuvant 
AS01 (GSK, Rixensart, Belgium and Antigenics Inc, USA) is a proprietary adjuvant system 
containing MPL (3-O-desacyl-4’-monophosphoryl lipid A), the saponin derived QS21 
combined with dioleoylphosphatidycholine (a phospholipid) and cholesterol. MPL is derived 
from the Salmonella Minnesota lipopolysaccharide and stimulates antigen presenting cells 
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expressing Toll-Like receptor 4 through activation of the innate immunity. QS21 is a 
molecule extracted from the South American tree Quillaja saponaria Molina fraction 21 and 
stimulates innate pathways in monocytes through an unclear mechanism (28). The 
liposomal formulation is thought to offset the intrinsic haemolytic activity of QS21 (29), but 
may also enhance antigen presentation when compared with its emulsion formulation AS02 
(30)  
The synergy between MPL and QS21 resulted in stimulation both classical and monocyte-
derived dendritic cells and enhances antigen presentation to T cells. Although within 
preclinical studies AS01 enhances IFN driven responses, clinical experience has shown that 
AS01 predominantly induces production of antigen-specific antibodies and specific CD4 
cells. AS01 has been used in candidate vaccines in hepatitis B, HIV and malaria with no 
safety concerns or increased risks of immune-mediated diseases (31). An increased risk of 
meningitis without clear aetiology was reported in the Phase 3 trial in children who received 
RTS,S/AS01 compared to control but the significance of this was unclear (32).  
Combination gE / AS01 in animal models  
Humoral and cellular mediated immune responses induced by recombinant gE formulated 
with AS01B adjuvant (‘B’ refers to the dilutions - 50 μg each of MPL and QS21) was 
investigated through a VZV-primed C57BL/6 mouse model (33). Mice immunised twice with 
gE formulated with AS01B resulted in significantly higher total frequencies of activated CD4 
cells and gE-specific CD4 cells producing IFN-γ and IL-2 when compared to formulation with 
alum or saline. The geometric mean concentrations of anti-gE antibody at day 30 were 
higher in mice vaccinated with gE/ AS01B. In direct comparison of AS01B with the oil 
emulsion-based adjuvant AS02 no significant differences in gE-specific CD4 cells were 
observed at day 30, although a higher frequency of IFN-γ was observed with ASO1B.   
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Clinical studies on HZ/Su  
Phase I/II trials in humans and safety, and immunogenicity in young subjects 
The safety and immunogenicity of the recombinant gE/AS01 candidate vaccine (HZ/Su) was 
examined in a phase I/II open-label, randomised study with 155 enrolled subjects (34). 
Through a staggered recruitment design 20 young adults (aged 18-30 years) and 135 older 
adults (aged 50-70 years) were randomised to receive two doses of: HZ/Su (50 μg 
recombinant VZV gE with AS01B), or HZ/Su and OKA, (a live attenuated Oka strain VZV 
vaccine containing approximately 104 PFU per dose injected subcutaneously) or OKA alone 
on months 0 and 2.   
Higher numbers of younger and older subjects who received a regimen containing HZ/Su 
experienced local symptoms when compared to the OKA only group - Up to 11% 
experienced pain at injection site at grade 3 severity (i.e. preventing normal daily activities) 
and 20% had > 50 mm of local redness. General reactions such as myalgia and fatigue were 
also more common in those receiving HZ/Su. No vaccine related serious adverse events 
(SAEs) or deaths were reported on follow up to month 42. 
Humoral immunogenicity measured through geometric mean concentrations (GMC) of 
serum anti-gE and anti-VZV antibody was higher in subjects immunised with HZ/Su or HZ/Su 
with OKA compared OKA alone. Antibody levels were highest after the first dose in young 
adults but after the second dose in the older group and anti-gE specific responses were 
greater than anti-VZV. At month 42 in those vaccinated with HZ/Su alone there was a 
decline of both anti-VZV and anti-gE GMCs although this remained higher when compared 
to baseline.  
Cellular immunity was measured through intracellular cytokine staining and T cells 
considered positive if they expressed at least 2 cytokines induction with VZV lysate or gE. T 
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cell responses were highest after 2 doses of HZ/Su or HZ/Su with OKA compared to 2 doses 
of OKA alone. The frequency of VZV-specific CD4 cells secreting at least 2 cytokines 
decreased to levels comparable baseline at month 30. Stimulation of CD8+ cells was not 
detected in any of the groups.  
The authors conclude that HZ/Su was generally tolerated and safe. Although appearing 
more immunogenic when compared with OKA alone they note that this may not translate 
into clinical efficacy given that the risks and immunological correlates of protection for HZ 
are still unclear (21).  
Phase I/II trials in older subjects> 50 years (Chilibek), safety and 3 different formulations 
(Chilibek) 
Two phase II, randomised multicentre studies conducted in parallel between 2007 and 2011 
and funded by GSK Biologicals investigated the impact of vaccine and adjuvant formulation 
on the safety and immunogenicity of the HZ/Su vaccine in older adults. 
In the vaccine formulation study (35) 714 patients aged ≥ 60 were recruited to receive two 
doses of trial vaccine 2 months apart. Subjects were randomised to receive two doses of 25 
μg or 50 μg or 100 μg of gE combined with AS01B two months apart, or saline in month 0 
followed by one dose of 100 μg gE/ AS01B, or two doses of unadjuvanted 100 μg gE two 
months apart. In the adjuvant study (36) 410 adults ≥ 50 years were randomised to receive 
two doses of 50 μg gE/ AS01B, or 50 μg gE/ AS01E  (a lower dose adjuvant containing 25 μg 
MPL and 25 μg QS21), or 50 μg gE unadjuvanted or saline two months apart.   
Similar to the previous study, injection site pain, fatigue, myalgia and headache were the 
most common reported symptoms and this was attributed to the adjuvant. Subjects in both 
studies who received a vaccine containing AS01 had a higher incidence of local and general 
reactions with the majority experiencing pain at injection site. Within the vaccine 
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formulation study < 6.1% of subjects reported a grade 3 local or general reaction; this 
incidence was higher in subjects aged 60-69 years compared to those over 70.  In adjuvant 
study up to 87% of subjects receiving gE adjuvant experienced local or general symptoms, of 
which 9.3% were classed as a grade 3 reaction. In contrast 5.3% in saline only group and 
2.7% in the gE/saline group experienced grade 3 reactions. Overall the majority of 
symptoms resolved within 3 days. In addition, solicited reactions were more frequent when 
the higher dose adjuvant (AS01B) was used when compared to lower dose (AS01E).  
At follow up through to 14 months no SAEs or deaths attributable to vaccination occurred in 
either study. 2 subjects withdrew due to treatment related AEs in the adjuvant formulation 
study. The authors comment that formulation with AS01 specifically was more immunogenic 
and induced more adverse reactions in its recipients. However, this did not lead to lower 
uptake of a second dose of the vaccine, and they conclude AS01 was overall well tolerated 
under trial conditions. 
Subjects who received 2 doses of gE/AS01 had higher anti-gE and anti-VZV titres at month 3 
compared to other groups, and those who received either 50 or 100 μg of gE with AS01B had 
higher GMCs than subjects who received 25 μg. These responses persist through to month 
36 and remained higher than pre-vaccination levels. A higher dose adjuvant with AS01B also 
elicited a stronger humoral response. Notably, based on the anti-VZV antibody criteria used, 
38.7% and 17.5% were non-responders with AS01B and AS01E respectively. The significance 
of this was unclear.  
Cellular immune responses were measured through intracellular cytokine staining of 
stimulated T cells and after adjustment frequencies were higher at month 3 for the 50 and 
100 μg gE/ AS01B groups compared two doses of 25 μg gE/ AS01B or one dose of 100 μg 
gE/AS01 or two doses of 100 μg gE/Saline groups. In the adjuvant study, cellular responses 
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were significantly higher in AS01B group compared to AS01E. Non-responder rates 
approximately <12% for gE-specific cellular immunity but 50% according to VZV cellular 
immunity. In both studies subjects ≥70 years old who received gE and AS01 showed similar 
levels of cellular immunity responses and immunogenicity at month 3 when compared to 
the other age groups. At 6 years follow up of 119 (out of 166) subjects who received 50 μg/ 
AS01B the gE-specific immunity remained 3.8 times higher than pre-vaccination levels (37). 
Phase III RCTs in 50s and 70s  
A multicentre phase 3 randomised placebo controlled trial ZOE-50 (ClinicalTrials.gov number 
NCT01165177, funded by GSK Biologicals) was performed between 2010 and 2011 (38). 
16,160 participants ≥ 50 years who were not immunosuppressed were randomised in a 1:1 
ratio to receive either HZ/Su vaccine (consisting of 50 μg gE with AS01B) or placebo (0.9% 
saline) at months 0 and 2. The investigators and participants were blinded to the 
intervention administered.  
A confirmed case of herpes zoster was defined as unilateral rash with sensory symptoms 
confirmed by a positive real-time polymerase chain reaction (PCR) result targeting VZV 
ORF62. Investigators were to examine suspected cases within 48 hours and obtain 
photographs of the lesions. If the PCR assay was negative for the internal positive control or 
if samples were unavailable, then diagnosis was established through unanimous agreement 
amongst 5 members of a committee through case review.  
14,759 (95.8%) of participants were included in the final analysis including exclusion of 749 
subjects due to Good Clinical Practice deviations. Most were recruited from Europe and 
71.8% were white and 61.2% were female. The mean age of all participants was 62.3 years 
old. 
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As with previous studies up to 84.4% participants in the HZ/Su group reported symptoms. 
17.2% of participants receiving HZ/Su reported grade 3 reactions lasting a median duration 
of 1 day, including 9.5% reporting local site reactions and 11.4% systemic symptoms. This 
compared with 3.2% of participants who received placebo reporting grade 3 reactions. In 
the first 30 days after vaccination 1 HZ/Su and 3 placebo recipients had a SAE related to 
vaccination. The occurrence and nature of potential immune-mediated diseases was not 
significantly different in the HZ/Su and placebo group (1.0 and 1.3% respectively throughout 
the study period). With a mean follow up of 3.5 years the incidences of SAEs and deaths 
were similar in both the HZ/Su and placebo group.  
408 participants reported suspected HZ of which 244 (59.8%) of these cases were 
confirmed. 33 cases were inconclusive and not included in final evaluation. After exclusion 
of participants who did not receive 2 doses of vaccine 216 confirmed cases of HZ were 
analysed – with 6 occurring in HZ/Su group and 210 in placebo group with a mean follow-up 
duration of 3.2 years. The overall rate of herpes zoster was 0.3 per 1,000 person-years in the 
HZ/Su cohort and 9.1 per 1,000 person-years in the placebo cohort.  The rate of HZ in the 
placebo cohort is comparable to population estimates (2). 
Notably the HZ rate in the HZ/Su group was similar across different age groups and the 
derived vaccine efficacy was approximately 97.2% at 3.2 years (95% confidence interval 93.7 
to 99.0%; p <0.001) with no significant difference across all age groups. 
A separate phase 3 randomised, placebo controlled multicentre trial ZOE-70 
(ClinicalTrials.gov NCT01165229, funded by GSK Biologicals) was performed in parallel with 
ZOE-50 between 2010 and 2011 to examine the efficacy and safety of the HZ/Su vaccine in 
adults older than 70 years old in reducing the incidence of HZ and PHN (39). 14,816 
participants were recruited to receive either HZ/Su or placebo in a 1:1 ratio. The protocols 
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for the assessment potential clinical cases of HZ were similar to ZOE-50 and assessment of 
PHN cases carried out through daily questionnaires for 28 days and follow up for at least 90 
days after onset of rash.  
13,163 (94.7%) participants with a mean age of 75.6 years were included in the final analysis 
cohort. 22.1% of the cohort were 80 years or older. Around 74.1% of participants who 
received HZ/Su experienced local reactions, 8.5% of which were of grade 3 severity. The 
authors observe that adverse reactions occurred less frequently in participants who were 
older than 80 years old compared to the 70 to 79-year-old group. The overall rate of grade 3 
adverse reactions in HZ/Su recipients in turn appear to be lower than that of the younger 
ZOE-50 cohort which received HZ/Su. With a mean follow up of 4 years the incidence of 
SAEs including deaths and immune mediated diseases were similar in the HZ/Su and placebo 
groups. 
246 cases of HZ occurred in the final modified vaccinated cohort – 23 in HZ/Su and 223 in 
placebo patients after a mean duration of 3.7 years. The incidence rate for HZ was 0.9 
cases/1000 person-years in the HZ/Su group and 9.2 cases/1,000 person-years in the 
placebo group. Vaccine efficacy in ZOE-70 was 89.8% (84.2 to 93.7, p <0.001) and 87.9% 
(95% CI 73.3 to 95.4) four years after vaccination. This did not differ significantly between 
the 70-79 and ≥ 80-year-old cohort.  
The calculation of vaccine efficacy against PHN included pooling of participants form the 
ZOE-50 trial. All patients who developed PHN were over 70 years of age. During a mean 
follow up of 3.8 years the incidence of PHN in the HZ/Su group was 0.1 cases/1000 person-
years and 0.9 cases/1000 person-years in the placebo group deriving a vaccine efficacy 
against PHN of 88.8% for participants 70 years or older. The incidence of PHN in HZ/Su 
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cohort who developed HZ was not significantly different to that in participants who received 
placebo. 
Phase I/II trials in adults with HIV infection 
Patients with HIV have a higher risk of developing HZ. This risk is attenuated but does not 
return to age-matched population rates after commencement of anti-retroviral therapy 
(ART) and remains approximately 3-5 times higher (40).  Although live attenuated vaccines 
are thought to be safe in patients with HIV with a CD4 count of greater than 200 mm3 its 
efficacy is not clear (BHIVA guidelines 2015 use of vaccines in HIV-positive).  
The safety and immunogenicity of the HZ/Su vaccine in a cohort of adults infected with 
human immunodeficiency virus (HIV) was supported through a randomised placebo 
controlled study (41). Three cohorts of subjects infected with HIV were recruited: 94 
subjects established on ART for at least a year and had a CD4 count of ≥ 200 cells/mm3, 14 
subjects on ART with a CD4 count of 50-199 cells/mm3, and 15 adults ART-naïve with a CD4 
count of ≥ 500. Each group was randomised to receive 3 doses of HZ/Su or 3 doses of saline 
at months 0, 2, and 6.  
123 subjects were enrolled and the majority (91.1%) completed follow up to month 18. 
Local and systemic adverse events were more common in the HZ/Su group but were short-
lived (median duration 1-3 days). Up to 16.4% of subjects receiving HZ/Su and 8.3% 
receiving saline experienced a grade 3 local or general reaction. Overall administration of 
HZ/Su had no impact on CD4 cell count, HIV viral load or haematological/biochemical 
parameters through month 18 of follow up.   
The overall magnitude of gE-specific cellular immunity and anti-gE antibody response was 
higher in the HZ/Su group compared to the saline. This was demonstrated in the combined 
cohort consisting of ART/high CD4 count and the ART naïve/high CD4 count cohort. The gE-
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specific cellular immunity did not increment dramatically after the third dose the HZ/Su 
vaccine and the authors conclude that a 2-dose schedule is likely to be appropriate for HIV 
infected adults.  
The authors comment that although the exact immunological correlates of clinical 
protection are not defined in HIV infection the HZ/Su vaccine was safe, and immunogenic in 
subjects with relatively high CD4 count. Because of the low numbers recruited in the 
ART/low CD4 group there was insufficient statistical power to assess the effects of 
vaccination within this cohort for which an efficacious subunit vaccine would be of most 
benefit.  
Phase 1/2 study in autologous haematopoietic stem cell transplant (HCT) recipients. 
Patients with haematopoietic stem cell transplants have rates of 15-30% of HZ during first 
year after transplantation  (42)  and furthermore this is associated with more severe 
complications such as disseminated infection.  
121 adult subjects who underwent autologous HCT within the previous 50-70 days between 
2009 and 2012 in the United States were randomised to receive: 3 doses of gE/ AS01B, or3 
doses of gE/ AS01E or 1 dose of saline with 2 doses of gE/ AS01B, or 3 doses of saline on 
months 0, 1 and 3 (43).   
Subjects who received gE/AS01 vaccines experienced a higher rate of symptoms with up to 
17.2% experiencing local reactions rated as grade 3. AS01B tended to be more reactogenic 
than the lower dose AS01E. One SAE was considered related to vaccination was reported up 
to month 15 but no deaths or immune mediated inflammatory disorders attributable to 
vaccination.   
At month 4 the overall gE-specific and VZV-specific CD4 cell frequency was higher in all 
gE/AS01 groups compared to saline. There was no significant difference in the CD4 response 
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between the 3 dose AS01B and the 3 dose AS01E. A similar relationship was also observed in 
terms of anti-gE antibody titres. Similar to previous studies the increase in immunogenicity 
after the 3rd dose of gE/AS01 was modest. 
Notably anti-gE GMCs with AS01B / AS01E did not increase in subjects with NHL B cell 
lymphoma. This was likely caused by B cell depletion through rituximab administration as 
part of underlying treatment. Given immune reconstitution and engraftment is brought by 
HCT and risk of HZ is greatest within 2 years of transplant even a modest short term 
protection may be beneficial and should be explored in further clinical studies.  
GSK approval 
In October 2016 GSK submitted a Biologics License Application to the United States Food 
and Drug Administration for approval of HZ/Su the prevention of herpes zoster and its 
complications in persons aged 50 years or over. In November 2016 applications were 
submitted to the European Medicines Agency and Health Canada.  
Conclusions 
An existing single dose of a live attenuated vaccine to prevent HZ is currently licensed in 52 
counties. However, there are understandable concerns about the efficacy of the vaccine, 
and the fact that it is contraindicated in a sub-section of the population. The results of the 
novel sub-unit vaccine, HZ/Su, have been eagerly awaited.  
HZ/Su has demonstrated immunogenicity in preclinical studies and efficacy in preventing HZ 
in clinical trials. The vaccine efficacy to prevent development of HZ at 4 years follow up was 
97% overall in subjects older than 50 years of age, and around 90% in participants older 
than 70 years old. More importantly the response appears preserved with age. In the ZOE-
50 and 70 studies the incidence of HZ within the vaccinated cohort remained similar 
between the age 60-69 and group ≥ 70-year-old group (0.7 and 0.9 cases per 1,000 person-
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years respectively). In the SPS incidence of HZ in the vaccinated group increased from 3.90 
cases per 1,000 person-years in the 60 to 69-year-old group to 7.18 per 1000 person-years 
in the ≥70-year-old group. Direct comparison of the two studies can be difficult given 
different primary end points were employed.  
The main burden of HZ remains PHN. Mainly through reduction in the incidence of HZ HZ/Su 
appears to be able to protect against PHN. The exact relationship between HZ and risk for 
PHN remains unclear. The authors note that the efficacy of HZ/Su in prevention of PHN does 
not extend beyond development of HZ. However, the low numbers of HZ onset in the 
vaccine groups make it difficult to draw conclusions.  
HZ/Su is reactogenic and local or general reactions are almost universal (up to 95% for 
example experience across all studies). The incidence of grade 3 reactions which prevent 
activities of daily living in addition around 10% may have a disproportionate impact on the 
willingness for patients outside trial conditions to take up the vaccine. In particular, the 
target population tends to be frail and older. SAEs and deaths were not increased between 
trial and placebo groups with follow up at 4 years in the overall pooled studies with no 
increase in the incidence of immune mediated diseases. 
Overall vaccine efficacy for HZ/Su for participants over 50 years of age appeared to decrease 
with time (from 96.6% at year 1 to 87.9% at year 4), however the authors conclude that the 
difference was not statistically significant and this will need to be followed up with longer 
term studies.  
Studies in immunocompromised patients unable to receive live attenuated vaccines have 
been encouraging, with immunogenicity and acceptability demonstrated in patients after 
HSCT and in HIV infection - although measurements of VZV immunity across the different 
HZ/Su trials have not been standardised. Within the HIV trial the few numbers of patients in 
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the low CD4 group completing the study meant analysis was not possible but the vaccine 
appeared safe.  
Future directions 
It has been predicted that the incidence of HZ will rise with the increasing ageing of the 
population. There were concerns that this would be particularly marked for several years 
after the introduction VZV vaccine in numerous countries. Interestingly, current 
epidemiological evidence suggests that the incidence of HZ in countries adopting the VZV 
vaccine has actually fallen (44). It is possible that wider uptake of the VZV vaccine will have a 
considerable reduce the burden of HZ, and the need for a vaccine.     
In terms of the current evidence, the trials have been conducted in areas where the 
majority of participants were VZV IgG positive. The impact of the vaccine on recipients who 
are VZV IgG negative, or have previously received the VZV/chickenpox vaccine will need to 
be evaluated. Given the reactogenicity of HZ/Su studies addressing its management may be 
important for acceptability outside clinical trial conditions. Although the introduction of 
routine childhood chickenpox vaccination is thought not to have contributed to the 
increasing incidence of shingles (44) the changing epidemiology of shingles and the impact 
of introducing a potentially expensive new vaccine need to be carefully examined.  
Clinical trials examining vaccine safety of HZ/Su in renal transplant recipients and vaccine 
efficacy in HSCT recipients are ongoing (ClinicalTrials.gov NCT02058589 and NCT01610414 
respectively). In addition, a direct head-to-head comparison study between Zostavax and 
HZ/Su in the elderly is underway (ClinicalTrials.gov NCT02114333). The outcomes of these 
studies may influence future vaccination policy on shingles in different subpopulations.  
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Figure 1&2: 1) Transmission electron microscopic (TEM) image of a VZV particle (CDC/ Dr Erskine Palmer and 
B.G. Partin). 2) Structure of VZV virus (Viralzone, SIB Swiss Institute of Bioinformatics).  
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Figure 3: The natural history of VZV infection. (Zerboni et al, 2014) 
 
